SARS-CoV

Severe acute respiratory syndrome is a life-threatening infectious disease caused by SARS-CoV. Although the spread of the virus has been controlled, the successful development of antiviral drugs against SARS-CoV is necessary for possible reappearance of SARS. All proteins and subcellular structures involved in the life cycle of CoVs are promising targets for the treatment of diseases caused by CoVs. Currently available antiviral drug discovery strategies, including advances in drug development based on different molecular targets: 1) compounds that block the S protein-ACE2-mediated viral entry; 2) compounds that target SARS-CoV M(pro); 3) compounds that target papain-like protease 2 (PLP2); 4) compounds that target SARS-CoV RdRp; 5 ) compounds that target SARS-CoV helicase.

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA that can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East Respiratory Syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CAS No.	Product Name	Inquiry
858956-95-3	Iodobananin Iodobananin is an effective inhibitor of the ATPase activity of the SARS Coronavirus (SCV) helicase.
86-01-1	Guanosine 5'-triphosphate Guanosine triphosphate (GTP) is a guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP functions as a carrier of phosphates and pyrophosphates involved in channeling chemical energy into specific biosynthetic pathways. GTP activates the signal transducing G proteins which are involved in various cellular processes including proliferation, differentiation, and activation of several intracellular kinase cascades. Proliferation and apoptosis are regulated in part by the hydrolysis of GTP by small GTPases Ras and Rho. Another type of small GTPase, Rab, plays a role in the docking and fusion of vesicles and may also be involved in vesicle formation. In addition to its role in signal transduction, GTP also serves as an energy-rich precursor of mononucleotide units in the enzymatic biosynthesis of DNA and RNA.
868273-90-9	ONO-5334 NO-5334 is cathepsin K inhibitor Ki values of 0.1 nM for human. It can improve bone strength by preferentially increasing cortical bone mass in ovariectomized rats. ONO-5334 can also inhibit N-terminal and C-terminal collagen crosslinks in serum and urine in postmenopausal women. In Feb 2012, Phase-II for Osteoporosis in European Union was discontinued.
870153-29-0	PF-00835231 PF-00835231 is a SARS-CoV-2 3CLpro inhibitor that has the potential as the treatment for COVID-19.
87205-99-0	Dihydrotanshinone I Dihydrotanshinone I is isolated from the roots of Salvia miltiorrhiza Bge. It exhibits dose-dependent inhibition towards HLM-catalyzed propofol glucuronidation.
88321-09-9	Aloxistatin Aloxistatin is an inhibitor of cathepsins B and L as well as a potential inhibitor of calpain, which predicted to function against SARS-CoV-2 infection.
883944-52-3	SSAA09E2 SSAA09E2 is a SARS-CoV inhibitor that acts by blocking early interactions of SARS-S with the receptor for SARS-CoV, angiotensin converting enzyme 2 (ACE2).
888958-25-6	SARS-CoV-IN-1 SARS-CoV-IN-1 is one of hydroxyferroquine derivatives with antimalarial and antiviral activities, and also an effective inhibitor of SARS-CoV replication.
888958-26-7	SARS-CoV-IN-2 SARS-CoV-IN-2 is one of hydroxyferroquine derivatives with antimalarial and antiviral activities, and also an effective inhibitor of SARS-CoV replication.
888958-27-8	SARS-CoV-IN-3 SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. It exhibits anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells.
890402-73-0	XP-59 Benzotriazole esters have been reported as potent nonpeptidic inhibitors of the enzyme, XP-59 is a potent inhibitor of the SARS-CoV M(pro).
896106-16-4	Imiquimod maleate Imiquimod maleate is an immune response modifier. It acts as a toll-like receptor 7 agonist. It is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. It can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes to activate the adaptive immune system when applied to skin.
89971-88-0	SARS-CoV-2-IN-21 SARS-CoV-2-IN-21 (compound 10), a penicillin sulfone benzyl C6 derivative, is a potent SARS-CoV-2 main protease inhibitor, with an IC50 of 5.3 μM. SARS-CoV-2-IN-21 can be used for COVID-19 research. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
91188-00-0	Merafloxacin Merafloxacin is a fluoroquinolone antibacterial agent, which inhibits -1 frameshifting efficiency of beta coronaviruses including SARS-CoV-2.
912799-11-2	SARS-CoV-2-nsp13-IN-5 SARS-CoV-2 nsp13-IN-5 (compound C6) is a potent SARS-CoV-2 nsp13 inhibitor with IC50 values of 50 and 55 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-5 can be used for researching anti-COVID-19.
923140-39-0	SARS-CoV-2-nsp13-IN-4 SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is druglike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect.
951588-85-5	SARS-CoV-2-nsp13-IN-6 SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA+ ATPase and ssDNA- ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19
96187-53-0	Brequinar Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Check for active clinical trials or closed clinical trials using this agent.
99011-78-6	Imiquimod hydrochloride Imiquimod hydrochloride is an immune response modifier. It acts as a toll-like receptor 7 agonist. It is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. It can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes to activate the adaptive immune system when applied to skin.
1093070-14-4	HY-17542 HY-17542 is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 μM.

※ Please kindly note that our services are for research use only.